RxDoctor Payments DataLook up a doctor →

Michael Rosario-Prieto, MD

Neuromuscular Medicine · St Petersburg, FLNPI 1871738948

Payments from drug & device makers

$471,492in general payments, 2019–2025

Across 872 payments — averaging $540.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$349K
  • UCB, Inc.$102K
  • UCB SA$4K
  • Amgen$2K
  • AbbVie$2K
  • AstraZeneca$2K
  • plus $10K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Argenx US, Inc.102$349,358
UCB, Inc.169$102,217
UCB SA1$3,995
Amgen12$2,488
AbbVie(2 entities)104$1,905
AstraZeneca(2 entities)31$1,736
Novartis41$711
Takeda Pharmaceuticals U.S.A., Inc.21$631
Biogen28$576
Genentech USA, Inc.21$570
Pfizer32$527
Teva Pharmaceuticals USA, Inc.36$472
GE HealthCare17$471
Tanabe Pharma America, Inc.16$469
Neurocrine Biosciences, Inc.23$414
Lundbeck LLC13$378
CSL Behring15$357
SK Life Science, Inc.7$309
Lilly USA, LLC14$289
Acorda Therapeutics, Inc12$284
Catalyst Pharmaceuticals, Inc.9$254
Vanda Pharmaceuticals Inc.9$200
Johnson & Johnson5$194
Acadia Pharmaceuticals Inc9$188
Sanofi8$179
Eisai Inc.8$161
Sumitomo Pharma America, Inc.8$147
Portola Pharmaceuticals, LLC8$141
Silk Road Medical, Inc.1$138
Merz Pharmaceuticals, LLC5$115
Aucta Pharmaceuticals, Inc.10$113
Upsher-smith Laboratories LLC5$106
Sunovion Pharmaceuticals Inc.6$104
Alnylam Pharmaceuticals Inc.4$97
Jazz Pharmaceuticals Inc.4$96
Banner Life Sciences, LLC4$96
EMD Serono, Inc.6$94
Supernus Pharmaceuticals, Inc.7$89
Sarepta Therapeutics, Inc.3$82
Grifols USA, LLC4$79
Axsome Therapeutics, Inc.3$76
Biohaven Pharmaceutical Holding Company Ltd.3$66
Xeris Pharmaceuticals, Inc.3$65
Neurelis, Inc.2$40
Biohaven Pharmaceuticals, Inc.2$38
TG Therapeutics, Inc.1$35
Harmony Biosciences LLC1$30
Zyla Life Sciences, Inc.2$28
Avanir Pharmaceuticals, Inc.2$26
MDD US Operations, LLC2$26
C2n Diagnostics, LLC1$23
Microtransponder, Inc.1$22
Vertical Pharmaceuticals, LLC1$21
Tonix Medicines, Inc.1$21
Livanova USA, Inc.1$20
Corium, LLC1$19
Cycle Pharmaceuticals Inc1$18
ITF Therapeutics LLC1$17
Amylyx Pharmaceuticals, Inc.1$17
Idorsia Pharmaceuticals US Inc1$16

How this compares

Too few neuromuscular medicine providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$218,064
Medicare patients
252
Services billed
13,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neuromuscular medicine in St Petersburg

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →